Lineage Cell Therapeutics, Inc. · AMEX:LCTX
Lineage Cell Therapeutics — Investor Presentation (January 2023)
37 slides from Lineage Cell Therapeutics's investor presentation, Jan 23, 2023
Slide 1: Corporate Presentation January 23, 2023
LINEAGE Cell Therapeutics From promise to people. Our mission is to pioneer a new branch of medicine based on the directed differentiation and transplant of allogeneic cells to patients CORPORATE PRESENTATION JANUARY 23, 2023 lineagecell.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. (“Lineage”). This presentation includes certain information obtained from trade and statistical services,
Slide 3: Lineage Cell Therapeutics Snapshot
Lineage Cell Therapeutics SRSpReehaeniars Broad Capabilities Highly Differentiated Validated Technology Cell manufacturing and transplant Allogeneic product Global partnership technology candidates for lead asset OpRegen® 5 3 $670M Cell types in active Product candidates in Partnership development a
Slide 4: Cell Therapy Pipeline - 100% Allogeneic
Cell Therapy Pipeline - 100% Allogeneic FIELD PROGRAM PHASE 1 PHASE 2 PHASE 3 PARTNERS ® OpRegen Genentech A Member of the Roche Grouf Ophthalmology Dry AMD with Geographic Atrophy (GA) ‘ ° oPct ciIRM Demyelination Spinal Cord Injury (SC) — © ANP'1 Preclinical Internally-owned Neurotology Auditory N
Slide 5: Lineage Technology: Two-Step Allogeneic Cell Production
Lineage Technology: Two-Step Allogeneic Cell Production Expansion | 2 Differentiation TETETE weTitiy 2° 3331 ==> @ Puripoten «= SRE Proprietary Cell Lines r (ES or iPS) Master and Working _ Guided | Cell Banks Differentiation (x100’s) (in-house cGMP) nea 2 = 2 * Pluripotent stem cell lines (PSCs) pr
Slide 6: Requirements for a Successful Cell Therapy
Requirements for a Successful Cell Therapy Control (Safety) & Reproducibility @ * Source line characterization, cell banking, versatile expansion systems + Differentiation process development; culture conditions, optimization * Analytical methods, in-process controls, release criteria Purity / Ident
Slide 7: RPE Cell Transplants to Treat Dry AMD
@-== LINEAGE m= Cell Therapeutics RPE Cell Transplants to Treat Dry AMD
Slide 8: Worldwide Collaboration for Dry AMD Genentech
Worldwide Collaboration for Dry AMD Genentech “Roche and Genentech embarked on an ambitious journey to revolutionise ophthalmology” attps:/www.celebrateife roche, com/explore/science/ophthaimology restoration A Member of the Roche Group —Creating allogeneic retinal pigment epithelial (RPE) cells to
Slide 9: Millions Suffer from Vision Loss due to Dry-AMD
Millions Suffer from Vision Loss due to Dry-AMD « Age-related macular degeneration (AMD) presents in two forms, wet and dry * Wet age-related macular degeneration (wet AMD) is usually caused by blood vessels that leak fluid or blood into the macula * Dry age-related macular degeneration (dry AMD) in
Slide 10: Lineage Approach - OpRegen, a Complete Approach
Lineage Approach - OpRegen, a “Complete” Approach OpRegen is a one-time injection of fully-differentiated RPE cells intended to: 1) replace and restore retinal tissue (anatomy), and 2) preserve or improve vision (function) Pre-Transplant i Post-Transplant ao” | is Photoreceptor recovery Was RPE cell
Slide 11: Phase 1/2a Trial Complete, Long-Term Follow-Up Ongoing
Phase 1/2a Trial Complete, Long-Term Follow-Up Ongoing Cohort 4 (Initial Efficacy) Cohorts 1-3 (Dose and Safety) E 12 Impaired Vision Patients 12 Legally Blind Patients $66960060066 Heeeeererete Generally well-tolerated, Cells delivered across entire area of no reports of rejection atrophy (n=5): 12
Slide 12: Improved Structure (Smaller GA) Detectable Within Three Months
Improved Structure (Smaller GA) Detectable Within Three Months OCT 2020 JAN 2021 A " FAF Image OCT Image FAF Image OCT Image Degenerated POR & SS Normalized L GA AREA: 3.56 mm2 ————._ GA AREA: 2.69 mm? = negative growth rate! Total area 3M GROWTHRATE: -0.87mm? (ANNUAL RATE - 3.48 mm?) SQRT transform
Slide 13: Re-Thinking the Dry AMD Treatment Paradigm
Re-Thinking the Dry AMD Treatment Paradigm ‘Roche) 125 YEARS Celebrate Life “The moment our goal shifted from preservation to restoration” “Our recent partnership with Lineage Cell Therapeutics...is one of the important routes we are pursuing.... The hope is that this treatment could not only slow d
Slide 14: Ongoing Development: Phase 2a Trial Genentech
Ongoing Development: Phase 2a Trial Genentech A Member of the Roche Group A multicenter, open-label, single arm clinical study in patients with geographic atrophy (GA), secondary to age-related macular degeneration ¢ Managed and funded by Genentech ° Seeks to optimize subretinal surgical delivery an
Slide 15: OpRegen - A Multi Billion-Dollar Opportunity
OpRegen - A Multi Billion-Dollar Opportunity * The only known reported clinical cases of outer retinal structure improvement with improved vision observed in five dry AMD patients * Market opportunity not limited by monogenic deficiencies (e.g., gene therapy) ¢ Well-tolerated; no cases of rejection
Slide 16: Replacing whole cells may provide restorative benefits
In certain settings, replacing whole cells may provide restorative benefits beyond the reach of traditional approaches #replaceandrestore 16
Slide 17: Repeating Success - OpRegen as a Case Study and Guide
Repeating Success — OpRegen as a Case Study and Guide Control (Safety) & Reproducibility Multiple clinical batches generated and released Extensive comparability testing performed ra Single source, master bank cell line No reports of rejection 99.5% Positive oe o w e wo Purity/Identity icti + Highly
Slide 18: Oligodendrocyte Cell Transplants for Spinal Cord Injuries
-2= LINEAGE m= Cell Therapeutics Oligodendrocyte Cell Transplants for Spinal Cord Injuries
Slide 19: Spinal Cord Injury (SCI) Burden & Unmet Needs
Spinal Cord Injury (SCI) Burden & Unmet Needs ¢ Approx. 18,000 cases per year (US)! « Primary feature of a SCI sates is loss of mobility * * A significant burden + Goalof OPCItherapyis j= for patients and to restore arm, hand, ee -— caregivers? andfingerfunction = = = “=== aE — 67% of patients are e
Slide 20: Oligodendrocyte Cells as a Solution - OPC1 for SCI
Oligodendrocyte Cells as a Solution —- OPC1 for SCI Transplanting oligodendrocytes may provide additional upper extremity function and improve quality of life Oligodendrocyte progenitor cells (OPCs) are precursors to the myelinating cells of the central nervous system Myelinating cells provide insul
Slide 21: OPC1 Manufacturing Improvements: Lower Impurities
OPC1 Manufacturing Improvements: Lower Impurities OPC-1 Impurity/non-targeted cell population profile by flow cytometry 30 25 20 15 % Positive 10 cha . i. Marker1 Marker2 Marker3 Marker4 MarkerS Marker6 Marker 7 ™ Original Clinical Material i Lineage Improved Process
Slide 22: OPC1 Triple Mechanisms of Action
OPC1 Triple Mechanisms of Action Preventing Cavitation Myelination of Axons Neurotrophic Factors shiverer mouse shimouse + aye: hoe “ ‘ ee = ae 22
Slide 23: Expected Recovery vs OPC1: Motor Function Gains
Expected Recovery’ vs OPC1: Motor Function Gains 4% No Improvement, _j No Increase | | 1 Motor Level Increase =2 Motor Level Increase Expected OPC1 Recovery" Clinical Results? A, Blight AR, Anderson KD. Outcome
Slide 24: Real-World Impacts from Motor Level Improvements
Real-World Impacts from Motor Level Improvements Motor level gains translate into meaningful improvements in self-care and large reductions in costs of care Cervical Injury Level Daily Home Care C1-3 24 Hour Attendant C4 18-24 Hour Attendant 6-12 Hours of “a Assistance / C6 4 Hours Housework C7-8 1
Slide 25: OPC1 Cervical Clinical Trial - Summary of Adverse Events
OPC1 Cervical Clinical Trial - Summary of Adverse Events Majority of adverse events were mild to moderate in severity All Treated Subjects (N=25) AEs SAEs Total 534 29 Related to OPC1 i 0 Related to Injection Procedure 20 Related to Tacrolimus 11 1 To date, there have been no serious adverse events
Slide 26: OPC1 Cervical Clinical Trial - Cell Engraftment
OPC1 Cervical Clinical Trial - Cell Engraftment 12- and 24-Month MRI Scans Indicate Durable Engraftment Cystic cavitation (syringomyelia) is a disorder which can damage nerve fibers and is expected to occur in ~80% of matched SCI cases MRIs show formation of a tissue matrix at the injury site, indic
Slide 27: OPC1 Thoracic & Cervical Clinical Trials Overview
OPC1 Thoracic & Cervical Clinical Trials Overview Thoracic phase 1 clinical trial (N=5) — All subjects followed for at least 10 years (Journal of Neurosurgery Spine, Vol 37, Issue 3, 2022) — No unexpected serious adverse events attributable to the OPC1 transplant: —No evidence of neurological declin
Slide 28: OPC1 Program Summary
OPC1 Program Summary Key Takeaways Next Steps Unmatched experience - one of the longest running trials in the field and first of its kind Indication of efficacy compared to best available matched control (32% two-level gain) Excellent overall safety profile — 5 years follow up in cervical SCI — 10 y
Slide 29: OPC1 Asset Overview
OPC1 Asset Overview OPC1 utilizes targeted cell replacement (similar to OpRegen for dry AMD) OPC1 has RMAT & Orphan Drug Designations OPC1 has received >$14M in grant support from CIRM OPC1 may have application in other demyelinating conditions “There's no reason to not look forward in the same way
Slide 30: Looking Ahead: Preclinical Programs
-2= LINEAGE m= Cell Therapeutics Looking Ahead: Preclinical Programs
Slide 31: Preclinical Cell Transplant Programs
Preclinical Cell Transplant Programs ANP1 Auditory neuron progenitor cells Intended to treat auditory neuropathy spectrum disorders (hearing loss) — Hearing loss afflicts >400 million people worldwide ¢ IP filed covering composition and methods of generating ANPs ¢ Preclinical studies: initiated Q1
Slide 32: Traditional Drug Discovery Pathway vs Lineage Technology
Traditional Drug Discovery Pathway vs Lineage Technology Process! (e.g., small molecule) Traditional Discovery Assay Library Hit to Structure-activity => Development Screen Lead relationship (SAR) High Attrition + Target Validation Risk Lineage PSC Differentiation Technology pclete) => No Target Val
Slide 33: VAC: An Antigen-Presentation Platform for Cancer and Infectious Diseases
@-== LINEAGE @ Cell Therapeutics VAC An Antigen-Presentation Platform for Cancer and Infectious Diseases 8 lung cancer patients treated to date
Slide 34: The VAC Platform: On Demand Cell Therapy Vaccine
The VAC Platform: On Demand Cell Therapy Vaccine * VAC consists of allogeneic (“off the shelf”) dendritic cells (DCs) * No production lag between diagnosis and treatment, as required for autologous or patient-specific therapies ¢ DCs are manufactured and loaded with either a tumor antigen (as a canc
Slide 35: VAC - A Platform for Many Product Candidates
VAC —A Platform for Many Product Candidates Expansion from a cell line A J VAC1 and VAC2 Immuno-Oncology * Positive phase 1 data in AML * Completed phase 1 in NSCLC, analyses ongoing CANCER RESEARCH UK Differentiation Tumor Antigen Loading °@ Other Immuno-oncology Programs * Partnerships based on ne
Slide 36: Lineage Corporate Profile
Lineage Corporate Profile Corporate Research & Manufacturing Headquarters Development Jerusalem BioPark, Carlsbad, California Carlsbad, California Israel Strong Financial Position Market Capitalization Employees $66.4M ~$260M' 77 Cash & equivalents at 9/30/22 (U.S. & Israel) *Based on common shares
Slide 37: The Patients Are Our Inspiration
The Patients Are Our Inspiration. - ~ = “neace | 000
Lineage Cell Therapeutics — Investor Presentation (January 2023) on 6ix